PE20060319A1 - Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona - Google Patents
Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinonaInfo
- Publication number
- PE20060319A1 PE20060319A1 PE2005000597A PE2005000597A PE20060319A1 PE 20060319 A1 PE20060319 A1 PE 20060319A1 PE 2005000597 A PE2005000597 A PE 2005000597A PE 2005000597 A PE2005000597 A PE 2005000597A PE 20060319 A1 PE20060319 A1 PE 20060319A1
- Authority
- PE
- Peru
- Prior art keywords
- ethinylestradiol
- chlormadinone acetate
- combination
- equal
- less
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UNA FORMA DE ADMINISTRACION ORAL QUE COMPRENDE: A) DE 21-25 UNIDADES DIARIAS DE UNA COMBINACION DE ETINILESTRADIOL EN IGUAL CANTIDAD O MENOR DE 25ug Y ACETATO DE CLORMADINONA EN CANTIDAD IGUAL O MENOR DE 5 mg; B) DE 7 A 3 UNIDADES DIARIAS QUE NO CONTIENEN HORMONAS. UNA FORMULACION QUE CONTIENE HORMONAS COMPRENDE: 20ug DE ETINILESTRADIOL Y 2mg DE ACETATO DE CLORMADINONA; Y UNA FORMULACION QUE NO CONTIENE HORMONA COMPRENDE: 3mg DE POVIDONA K30; LACTOSA 32mg; FECULA DE MAIZ 12mg; ESTEARATO DE MAGNESIO 0,5mg; DIOXIDO DE SILICIO ALTAMENTE DISPERSO 0,5mg. EL EMPLEO DE ACETATO DE CLORMADINONA GARANTIZA UNA SEGURIDAD ANTICONCEPTIVA ELEVADA Y SE CARACTERIZA POR SUS MARCADAS PROPIEDADES ANTIANDROGENAS, SIENDO UTILES PARA LA ANTICONCEPCION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004026670A DE102004026670A1 (de) | 2004-05-28 | 2004-05-28 | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060319A1 true PE20060319A1 (es) | 2006-06-15 |
Family
ID=34970113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005000597A PE20060319A1 (es) | 2004-05-28 | 2005-05-27 | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona |
Country Status (8)
Country | Link |
---|---|
US (1) | US9278072B2 (es) |
EP (1) | EP1753408B1 (es) |
AR (1) | AR049197A1 (es) |
DE (1) | DE102004026670A1 (es) |
ES (1) | ES2718636T3 (es) |
HU (1) | HUE043200T2 (es) |
PE (1) | PE20060319A1 (es) |
WO (1) | WO2005115351A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004026671A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Darreichungsform zur hormonalen Kontrazeption |
US20090117184A1 (en) * | 2007-11-05 | 2009-05-07 | Sabine Fricke | Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception |
AT12800U1 (de) * | 2007-11-05 | 2012-11-15 | Bayer Schering Pharma Ag | Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
WO2016203009A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
GEP20217243B (en) | 2015-06-18 | 2021-04-26 | Sprl Estetra | Orodispersible dosage unit containing an estetrol component |
HUE054551T2 (hu) | 2015-06-18 | 2021-09-28 | Estetra Sprl | Ösztetrolt tartalmazó, szájban diszpergálódó tabletta |
NO3106148T3 (es) | 2015-06-18 | 2018-08-11 | ||
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4635051A (en) | 1983-09-26 | 1987-01-06 | Tektronix, Inc. | High-speed electro-optical light gate and field sequential full color display system incorporating same |
WO1986001402A1 (en) | 1984-09-05 | 1986-03-13 | Schering Aktiengesellschaft | Means for handling androgenization phenomena and use of antiandrogens for the production thereof |
DK174724B1 (da) | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
DE3916112A1 (de) | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
DE4104385C1 (es) * | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
DE4224534A1 (de) * | 1992-07-24 | 1994-01-27 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
DE4308406C1 (de) * | 1993-03-12 | 1994-06-16 | Jenapharm Gmbh | Kombinationspräparat zur Kontrazeption |
DE4339934C2 (de) | 1993-05-07 | 1995-05-24 | Klaus Dr Med Umbreit | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
DE4321957C2 (de) | 1993-07-01 | 1995-09-28 | Marika Dr Med Ehrlich | Verwendung eines hormonalen Mittels zur Therapie der Akne |
DE4344462C2 (de) | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
DE19539233A1 (de) | 1995-10-21 | 1997-04-24 | Klaus Dr Med Umbreit | Oral einzunehmendes ovulationshemmendes Mittel |
US6511970B1 (en) * | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
DE19705229C2 (de) * | 1997-02-12 | 1999-04-15 | Hesch Rolf Dieter Prof Dr Med | Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US6326392B1 (en) * | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
TR200002995T2 (tr) * | 1998-04-17 | 2001-01-22 | Ortho-Mcneil Pharmaceutical,Inc. | Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri |
US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
DE10045380A1 (de) * | 2000-09-14 | 2002-04-04 | Schering Ag | Verfahren zur Kontrazeption und dessen Darreichungsform |
EP1293210B1 (en) * | 2001-05-23 | 2003-11-19 | Pantarhei Bioscience B.V. | Means and method for hormonal contraception |
WO2002094276A1 (en) | 2001-05-18 | 2002-11-28 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
MXPA05001803A (es) * | 2002-08-15 | 2005-08-16 | Wyeth Corp | Agonismo del receptor de 5ht2a para el tratamiento de disfuncion termorreguladora. |
EP1624848A4 (en) | 2003-05-02 | 2009-02-25 | Duramed Pharmaceuticals Inc | METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE |
-
2004
- 2004-05-28 DE DE102004026670A patent/DE102004026670A1/de not_active Withdrawn
- 2004-12-10 US US11/009,938 patent/US9278072B2/en not_active Expired - Fee Related
-
2005
- 2005-05-27 ES ES05750711T patent/ES2718636T3/es active Active
- 2005-05-27 EP EP05750711.3A patent/EP1753408B1/de active Active
- 2005-05-27 AR ARP050102213A patent/AR049197A1/es unknown
- 2005-05-27 HU HUE05750711A patent/HUE043200T2/hu unknown
- 2005-05-27 WO PCT/EP2005/005763 patent/WO2005115351A1/de active Application Filing
- 2005-05-27 PE PE2005000597A patent/PE20060319A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE102004026670A1 (de) | 2005-12-15 |
HUE043200T2 (hu) | 2019-08-28 |
ES2718636T3 (es) | 2019-07-03 |
WO2005115351A1 (de) | 2005-12-08 |
US9278072B2 (en) | 2016-03-08 |
EP1753408A1 (de) | 2007-02-21 |
US20050267084A1 (en) | 2005-12-01 |
EP1753408B1 (de) | 2019-01-02 |
AR049197A1 (es) | 2006-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060319A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
AR097341A2 (es) | Composición farmaceutica que comprende una dispersión de macrólidos sólidos, y un proceso para producir una tableta dispersable que contiene un macrólido | |
NZ597239A (en) | Pharmaceutical composition for emergency contraception | |
BR0009437A (pt) | Amido pré-gelatinizado em uma formulação de liberação controlada | |
CO5190672A1 (es) | Composicion para la dosificacion oral, de disolucion instantanea | |
HUP0303182A2 (hu) | Gyógyászati készítmények | |
TW200605882A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
GT200900090A (es) | Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina | |
WO2007048219A3 (en) | Sustained drug release composition | |
AR059174A1 (es) | Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas) | |
BRPI0408396A (pt) | pelìculas de dissolução rápida, consumìveis por via oral, contendo agentes farmaceuticamente ativos | |
NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
AR022008A1 (es) | Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento | |
HUP0401714A2 (hu) | Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái | |
BRPI0512993A (pt) | uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto | |
CL2009002187A1 (es) | Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06). | |
IL166432A0 (en) | Composition containing an androgenous 11?-halogen steroid and a progestational hormone and male contraceptive based on said composition | |
CR7611A (es) | Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona | |
CL2007001961A1 (es) | Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo. | |
GEP20063882B (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
WO2007062483A8 (en) | Increasing pregnancy rates | |
PL402550A1 (pl) | Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika | |
AR049196A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
AP1485A (en) | Orally administered controlled delivery system for once daily administration of ciprofloxacin. | |
ATE395047T1 (de) | Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |